192 related articles for article (PubMed ID: 17431753)
1. Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake.
Laplanche R; Meno-Tetang GM; Kawai R
J Pharmacokinet Pharmacodyn; 2007 Jun; 34(3):373-400. PubMed ID: 17431753
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients.
Moes DJ; Press RR; den Hartigh J; van der Straaten T; de Fijter JW; Guchelaar HJ
Clin Pharmacokinet; 2012 Jul; 51(7):467-80. PubMed ID: 22624503
[TBL] [Abstract][Full Text] [Related]
3. Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.
Pawaskar DK; Straubinger RM; Fetterly GJ; Hylander BH; Repasky EA; Ma WW; Jusko WJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1219-29. PubMed ID: 23455451
[TBL] [Abstract][Full Text] [Related]
4. Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125.
Kawai R; Lemaire M; Steimer JL; Bruelisauer A; Niederberger W; Rowland M
J Pharmacokinet Biopharm; 1994 Oct; 22(5):327-65. PubMed ID: 7791036
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of everolimus.
Kirchner GI; Meier-Wiedenbach I; Manns MP
Clin Pharmacokinet; 2004; 43(2):83-95. PubMed ID: 14748618
[TBL] [Abstract][Full Text] [Related]
6. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses.
Meno-Tetang GM; Li H; Mis S; Pyszczynski N; Heining P; Lowe P; Jusko WJ
Drug Metab Dispos; 2006 Sep; 34(9):1480-7. PubMed ID: 16751263
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents.
O'Reilly T; McSheehy PM; Kawai R; Kretz O; McMahon L; Brueggen J; Bruelisauer A; Gschwind HP; Allegrini PR; Lane HA
Cancer Chemother Pharmacol; 2010 Mar; 65(4):625-39. PubMed ID: 19784839
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications.
Kovarik JM; Hsu CH; McMahon L; Berthier S; Rordorf C
Clin Pharmacol Ther; 2001 Sep; 70(3):247-54. PubMed ID: 11557912
[TBL] [Abstract][Full Text] [Related]
9. Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats.
Yokomasu A; Yano I; Sato E; Masuda S; Katsura T; Inui K
Biopharm Drug Dispos; 2009 Dec; 30(9):517-23. PubMed ID: 19790241
[TBL] [Abstract][Full Text] [Related]
10. Physiologically Based Pharmacokinetic Modeling Involving Nonlinear Plasma and Tissue Binding: Application to Prednisolone and Prednisone in Rats.
Li X; DuBois DC; Almon RR; Jusko WJ
J Pharmacol Exp Ther; 2020 Nov; 375(2):385-396. PubMed ID: 32883831
[TBL] [Abstract][Full Text] [Related]
11. Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats.
Yokomasu A; Yano I; Sato E; Masuda S; Katsura T; Inui K
Drug Metab Pharmacokinet; 2008; 23(6):469-75. PubMed ID: 19122342
[TBL] [Abstract][Full Text] [Related]
12. Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics.
Kovarik JM; Noe A; Berthier S; McMahon L; Langholff WK; Marion AS; Hoyer PF; Ettenger R; Rordorf C
J Clin Pharmacol; 2003 Feb; 43(2):141-7. PubMed ID: 12616666
[TBL] [Abstract][Full Text] [Related]
13. Distribution of sirolimus in rat tissue.
Napoli KL; Wang ME; Stepkowski SM; Kahan BD
Clin Biochem; 1997 Mar; 30(2):135-42. PubMed ID: 9127695
[TBL] [Abstract][Full Text] [Related]
14. A Δ
Methaneethorn J; Poomsaidorn C; Naosang K; Kaewworasut P; Lohitnavy M
Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):495-511. PubMed ID: 32266676
[TBL] [Abstract][Full Text] [Related]
15. Physiologically Based Pharmacokinetic Modeling: The Reversible Metabolism and Tissue-Specific Partitioning of Methylprednisolone and Methylprednisone in Rats.
Yu R; Jusko WJ
Drug Metab Dispos; 2024 Jun; 52(7):662-672. PubMed ID: 38653502
[TBL] [Abstract][Full Text] [Related]
16. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
Xia B; Heimbach T; Lin TH; He H; Wang Y; Tan E
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1567-82. PubMed ID: 22526410
[TBL] [Abstract][Full Text] [Related]
17. The role of therapeutic monitoring of everolimus in solid organ transplantation.
Mabasa VH; Ensom MH
Ther Drug Monit; 2005 Oct; 27(5):666-76. PubMed ID: 16175142
[TBL] [Abstract][Full Text] [Related]
18. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients.
Budde K; Neumayer HH; Lehne G; Winkler M; Hauser IA; Lison A; Fritsche L; Soulillou JP; Fauchald P; Dantal J;
Nephrol Dial Transplant; 2004 Oct; 19(10):2606-14. PubMed ID: 15316094
[TBL] [Abstract][Full Text] [Related]
19. Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Junghanss C; Rathsack S; Wacke R; Weirich V; Vogel H; Drewelow B; Mueller S; Altmann S; Freund M; Lange S
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1061-8. PubMed ID: 22182476
[TBL] [Abstract][Full Text] [Related]
20. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.
Tanaka C; O'Reilly T; Kovarik JM; Shand N; Hazell K; Judson I; Raymond E; Zumstein-Mecker S; Stephan C; Boulay A; Hattenberger M; Thomas G; Lane HA
J Clin Oncol; 2008 Apr; 26(10):1596-602. PubMed ID: 18332467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
